Electrophysiologic profile of dronedarone on the ventricular level: Beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 1, 2012, Pages 92-100

  Milberg, Peter ^a   Frommeyer, Gerrit ^a   Uphaus, Timo ^a   Kaiser, Dennis ^a   Osada, Nani ^b   Breithardt, Günter ^a   Eckardt, Lars ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

amiodarone; dispersion of repolarization; dronedarone; proarrhythmia; sotalol; therapeutic safety; torsade de pointes

Indexed keywords

AMIODARONE; DRONEDARONE; POTASSIUM; SOTALOL;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; HUMAN; HUMAN TISSUE; ISOLATED HEART; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES;

ACTION POTENTIALS; AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HEART VENTRICLES; LONG QT SYNDROME; PERFUSION; RABBITS; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SOTALOL; TORSADES DE POINTES; VENTRICULAR FUNCTION;

EID: 84855340766     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182377a11     Document Type: Article

References (49)

1. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010; 21:597-605.
2. Hohnloser SH, Crijns HJ, van EM, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360: 668-678.
3. Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481-1487. (Pubitemid 37010577)
4. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001;104: 2722-2727. (Pubitemid 33108141)
5. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol. 1998;21:1029-1034.
6. Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther. 2002;300:64-71. (Pubitemid 34028509)
7. Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002;303:218-225.
8. Milberg P, Frommeyer G, Kleideiter A, et al. Antiarrhythmic effects of free polyunsaturated fatty acids in an experimental model of LQT2 and LQT3 due to suppression of early afterdepolarizations and reduction of spatial and temporal dispersion of repolarization. Heart Rhythm. 2011;8: 1492-1500.
9. Gautier P, Guillemare E, Marion A, et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol. 2003;41:191-202. (Pubitemid 36135243)
10. Fink A, Duray GZ, Hohnloser SH. A patient with recurrent atrial fibrillation and monomorphic ventricular tachycardia treated successfully with dronedarone. Europace. 2011;13:284-285.
11. Shaaraoui M, Freudenberger R, Levin V, et al. Suppression of ventricular tachycardia with dronedarone: a case report. J Cardiovasc Electrophysiol. 2011;22:201-202.
12. Kirchhof P, Degen H, Franz MR, et al. Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation. J Pharmacol Exp Ther. 2003;305:257-263. (Pubitemid 36373859)
13. Candinas R, Frielingsdorf J, Ha HR, et al. Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. Eur J Clin Pharmacol. 1998;53:331-336. (Pubitemid 28067973)
14. Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol. 2002;39:677-684. (Pubitemid 34453953)
15. Kamiya K, Nishiyama A, Yasui K, et al. Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation. 2001;103:1317-1324. (Pubitemid 32221358)
16. Elonen E, Neuvonen PJ, Tarssanen L, et al. Sotalol intoxication with prolonged Q-T interval and severe tachyarrhythmias. Br Med J. 1979;1:1184. (Pubitemid 9181409)
17. Milberg P, Ramtin S, Monnig G, et al. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. J Cardiovasc Pharmacol. 2004;44:278-286. (Pubitemid 39129444)
18. Eckardt L, Haverkamp W, Mertens H, et al. Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d, l-sotalol, and erythromycin. J Cardiovasc Pharmacol. 1998;32:425-434. (Pubitemid 28399672)
19. Eckardt L, Haverkamp W, Gottker U, et al. Divergent effect of acute ventricular dilatation on the electrophysiologic characteristics of d, l-sotalol and flecainide in the isolated rabbit heart. J Cardiovasc Electro-physiol. 1998;9:366-383. (Pubitemid 28183536)
20. Milberg P, Tegelkamp R, Osada N, et al. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. J Cardiovasc Electrophysiol. 2007;18:658-664. (Pubitemid 46800513)
21. Kirchhof PF, Fabritz CL, Franz MR. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: anti-arrhythmic and proarrhythmic effects. Circulation. 1998;97:2567-2574. (Pubitemid 28294504)
22. Eckardt L, Haverkamp W, Borggrefe M, et al. Experimental models of torsade de pointes. Cardiovasc Res. 1998;39:178-193. (Pubitemid 28322389)
23. Milberg P, Reinsch N, Osada N, et al. Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol. 2005;100:365-371. (Pubitemid 40974087)
24. Milberg P, Hilker E, Ramtin S, et al. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol. 2007;18:647-654. (Pubitemid 46800509)
25. Lalevee N, Nargeot J, Barrere-Lemaire S, et al. Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol. 2003;14:885-890. (Pubitemid 37006354)
26. Cerrone M, Noujaim S, Jalife J. The short QT syndrome as a paradigm to understand the role of potassium channels in ventricular fibrillation. J Intern Med. 2006;259:24-38.
27. Bogdan R, Goegelein H, Ruetten H. Effect of dronedarone on Na+, Ca2+ and HCN channels. Naunyn Schmiedebergs Arch Pharmacol. 2011;383: 347-356.
28. Burashnikov A, Belardinelli L, Antzelevitch C. Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm. 2010;7:1273-1279.
29. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219-233. (Pubitemid 30625285)
30. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357: 987-999. (Pubitemid 47367078)
31. Verduyn SC, Vos MA, Leunissen HD, et al. Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias. J Cardiovasc Pharmacol. 1999;33:212-222. (Pubitemid 29066661)
32. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation. 1999;100:2276-2281.
33. Huikuri HV, Yli-Mayry S. Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle. Pacing Clin Electrophysiol. 1992;15(pt 2):2103-2107.
34. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 1990;81:686-690. (Pubitemid 20055978)
35. Frommeyer G, Milberg P, Witte P, et al. A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. Eur J Heart Fail. 2011;13:1060-1069.
36. Zabel M, Hohnloser SH, Behrens S, et al. Differential effects of D-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. J Cardiovasc Electrophysiol. 1997; 8:1239-1245. (Pubitemid 27490692)
37. Vos MA, Gorenek B, Verduyn SC, et al. Observations on the onset of torsade de pointes arrhythmias in the acquired long QT syndrome. Cardiovasc Res. 2000;48:421-429.
38. Moro S, Ferreiro M, Celestino D, et al. In vitro effects of acute amiodarone and dronedarone on epicardial, endocardial, and M cells of the canine ventricle. J Cardiovasc Pharmacol Ther. 2007;12:314-321. (Pubitemid 350264696)
39. Shimizu W, Ohe T, Kurita T, et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol. 1995;26: 1299-1309.
40. Verduyn SC, Vos MA, van der Zande J, et al. Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired torsade de pointes arrhythmias: a comparison between almokalant and d-sotalol using the dog as its own control. J Am Coll Cardiol. 1997;30:1575-1584. (Pubitemid 27486478)
41. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation. 2001;103: 2004-2013. (Pubitemid 32322230)
42. Sipido KR, Varro A, Eisner D. Sodium calcium exchange as a target for antiarrhythmic therapy. Handb Exp Pharmacol. 2006;171:159-199.
43. Hondeghem LM, Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J Cardiovasc Pharmacol. 2003;41:14-24. (Pubitemid 36015051)
44. Habbab MA, el-Sherif N. Drug-induced torsades de pointes: role of early afterdepolarizations and dispersion of repolarization. Am J Med. 1990;89: 241-246. (Pubitemid 20254453)
45. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156:527-529.
46. Kowey PR, Singh BN. Dronedarone in patients with implantable defibrillators Heart Rhythm Society 2004 Scientific Session, Late Breaking Clinical Trials Oral Presentation; May 22, 2004; San Francisco, CA.
47. Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54:1089-1095.
48. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358: 2678-2687. (Pubitemid 351860860)
49. FDA Drug Safety Communication: Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events. July 27, 2011.